Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Citigroup Downgrades Aerie Pharmaceuticals to Neutral

Citigroup Downgrades Aerie Pharmaceuticals to Neutral

Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.

Legal
News

Department Of Labor Cites Dollar Tree Again For Endangering Workers, Continuing Company’s Lengthy History Of Workplace Safety Violations

By Benzinga Newsdesk

December 1, 12:03 PM

https://www.dol.gov/newsroom/releases/osha/osha20221201

DLTR

Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug

By Vandana Singh

September 8, 10:11 AM

Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) two pivotal trials evaluating aflibercept 8 mg with 12- and 16-week dosing regimens met the primary…

BAYRY

Google’s Dominance in Ad Tech Under Scrutiny, EU Alleges Antitrust Breach, Suggests Compulsory Divestment

By Vandana Singh

June 14, 8:06 AM

Alphabet Inc's (NASDAQ: GOOG) (NASDAQ: GOOGL) Google has been accused by the European Union of violating antitrust regulations in the field of advertising technology (ad tech).

GOOG

Morgan Stanley Maintains Equal-Weight on Timken, Raises Price Target to $83

By Benzinga Newsdesk

December 14, 12:55 PM

Morgan Stanley analyst Courtney Yakavonis maintains Timken (NYSE:TKR) with a Equal-Weight and raises the price target from $70 to $83.

TKR

Citigroup Downgrades Aerie Pharmaceuticals to Neutral

Related Posts

Department Of Labor Cites Dollar Tree Again For Endangering Workers, Continuing Company’s Lengthy History Of Workplace Safety Violations

Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug

Google’s Dominance in Ad Tech Under Scrutiny, EU Alleges Antitrust Breach, Suggests Compulsory Divestment

Morgan Stanley Maintains Equal-Weight on Timken, Raises Price Target to $83